Mecasermin Recombinant Patent Expiration
Mecasermin Recombinant is Used for treating primary IGF-1 deficiency. It was first introduced by Ipsen Biopharmaceuticals Inc
Mecasermin Recombinant Patents
Given below is the list of patents protecting Mecasermin Recombinant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Increlex | US5681814 | Formulated IGF-I Composition |
Sep 18, 2017
(Expired) | Ipsen Inc |
| Increlex | US5824642 | Treatment of partial growth hormone insensitivity syndrome |
Jul 08, 2014
(Expired) | Ipsen Inc |
| Increlex | US6207640 | Treatment of partial growth hormone insensitivity syndrome |
Apr 07, 2014
(Expired) | Ipsen Inc |
Mecasermin Recombinant's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List